Duration of treatment Indefinite v Sample Clauses

Duration of treatment Indefinite v. Adverse effects Nausea, vomiting, weakness, tachycardia, somnolence, headache, dizziness, vertigo, pain, parasthesia, neutropaenia and alterations in liver function tests. Transient increases in ALT can occur in the first 3 months of treatment, with levels returning to below twice the upper limit of normal after 2 to 6 months while treatment continues. vi. Monitoring Requirements LFT and FBC before and during therapy, every month for 3 months, then every 3 months for a further 9 months, and annually thereafter. ALT levels should be measured more frequently in patients who develop elevated ALT levels. Riluzole should be discontinued if ALT levels increase to five times the ULN. There is limited experience with dose reduction or re-challenge in these patients. Patients should be warned to report any febrile illness to their physicians. White blood cell counts should be checked and riluzole discontinued if WBC <3.5 or neutrophils < 2.0. Patients should be warned to report respiratory symptoms to their physician. Chest radiography should be performed and in case of findings suggestive of interstitial lung disease, riluzole should be discontinued immediately. vii. Clinically relevant drug interactions No clinical data available but since riluzole is extensively metabolised by the enzyme cytochrome P450 1A2, inhibitors (e.g. theophylline, quinolones) and inducers (e.g. rifampicin, omeprazole) of this enzyme could potentially affect the rate of elimination. Consult product literature for more details. viii. Contraindication Hepatic disease or baseline transaminases greater than 3 times the Upper Limit of Normal (ULN). Renal impairment, pregnancy, breast feeding
AutoNDA by SimpleDocs

Related to Duration of treatment Indefinite v

  • Equality of Treatment Unless otherwise provided in this Agreement, the persons specified in Article 3, who ordinarily reside in the territory of a Contracting State, shall receive equal treatment with nationals of that Contracting State in the application of the legislation of that Contracting State.

  • National Treatment and Most-favoured-nation Treatment (1) Each Contracting Party shall accord to investments of investors of the other Contracting Party, treatment which shall not be less favourable than that accorded either to investments of its own or investments of investors of any third State.

  • Substance Abuse Treatment Information Substance abuse treatment information shall be maintained in compliance with 42 C.F.R. Part 2 if the Party or subcontractor(s) are Part 2 covered programs, or if substance abuse treatment information is received from a Part 2 covered program by the Party or subcontractor(s).

  • PRESERVATION OF TAX AND ACCOUNTING TREATMENT Except as contemplated by this Agreement or the Registration Statement, after the Funding and Consummation Date, TCI shall not and shall not permit any of its subsidiaries to undertake any act that would jeopardize the tax-free status of the organization, including without limitation:

  • Xxx Treatment We have not promised you any particular tax outcome from buying or holding the Note.

  • Fair Treatment The College and the Union agree that there shall be no discrimination, restriction, or coercion exercised or practised with respect to any employee for reason of membership or activity in the Union.

  • Treatment of Investment Advice The Trust shall treat the investment advice and recommendations of JCM as being advisory only, and shall retain full control over its own investment policies. However, the Trustees may delegate to the appropriate officers of the Trust, or to a committee of the Trustees, the power to authorize purchases, sales or other actions affecting the portfolio of the Fund in the interim between meetings of the Trustees.

  • Future Treatment of Unallowable Costs Unallowable Costs shall be separately determined and accounted for by Xx. Xxxxxxx, and Xx. Xxxxxxx shall not charge such Unallowable Costs directly or indirectly to any contracts with the United States or any State Medicaid program, or seek payment for such Unallowable Costs through any cost report, cost statement, information statement, or payment request submitted by Xx. Xxxxxxx or any of its subsidiaries or affiliates to the Medicare, Medicaid, TRICARE, or FEHBP Programs.

  • Corporate Treatment The Board shall use its reasonable best efforts to take such actions as are necessary or appropriate to preserve the status of the Company as a partnership for U.S. federal (and applicable state and local) income tax purposes. If, however, the Board determines, in its sole discretion, for any reason (including the proposal, formally or informally, of legislation that could affect the Company’s status as a partnership for U.S. federal and/or applicable state and local income tax purposes) that it is not in the best interests of the Company to be characterized as a partnership, the Board may take whatever steps, if any, are needed to cause the Company to be or confirm that the Company will be treated as an association or as a publicly traded partnership taxable as a corporation for U.S. federal (and applicable state and local) income tax purposes, including by making an election to be taxed as a “C” corporation pursuant to the Code (a “Change in Tax Classification”), without any approval or vote of the Members required, and to make such filings, including without limitation, a Form 8832 with the Service, and to undertake such actions as required to effect such Change in Tax Classification. At the time and following any Change of Tax Classification, the Board shall have the right, without any approval or vote of the Members being required, to amend this Agreement as reasonably required to effect the Change in Tax Classification and to provide for the operations of the Company following such event. Notwithstanding anything in this Agreement to the contrary, in the event U.S. federal (and/or applicable state and local) income tax laws, rules or regulations are enacted, amended, modified or applied after the date hereof in such a manner as to require or necessitate that the Company no longer be treated as a partnership for U.S. federal (and/or applicable state and local) income tax purposes, then the first sentence of this Section 8.7 shall no longer apply.

  • Certification Regarding Debarment, Suspension, and Other Responsibility Matters Primary Covered Transactions

Time is Money Join Law Insider Premium to draft better contracts faster.